Cyclooxygenase-2 inhibitor blocks the production of West Nile virus-induced neuroinflammatory markers in astrocytes by Verma, Saguna et al.
Cyclooxygenase-2 inhibitor blocks the production
of West Nile virus-induced neuroinflammatory
markers in astrocytes




Received 9 September 2010
Accepted 19 November 2010
Retrovirology Research Laboratory, Department of Tropical Medicine, Medical Microbiology and
Pharmacology, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, HI
96813, USA
Inflammatory immune responses triggered initially to clear West Nile virus (WNV) infection later
become detrimental and contribute to the pathological processes such as blood–brain barrier
(BBB) disruption and neuronal death, thus complicating WNV-associated encephalitis (WNVE). It
has been demonstrated previously that WNV infection in astrocytes results in induction of multiple
matrix metalloproteinases (MMPs), which mediate BBB disruption. Cyclooxygenase (COX)
enzymes and their product, prostaglandin E2 (PGE2), modulate neuroinflammation and regulate
the production of multiple inflammatory molecules including MMPs. Therefore, this study
determined and characterized the pathophysiological consequences of the expression of COX
enzymes in human brain cortical astrocytes (HBCAs) following WNV infection. Whilst COX-1
mRNA expression did not change, WNV infection significantly induced RNA and protein
expression of COX-2 in HBCAs. Similarly, PGE2 production was also enhanced significantly in
infected HBCAs and was blocked in the presence of the COX-2-specific inhibitor NS-398, thus
suggesting that COX-2, and not COX-1, was the source of the increased PGE2. Treatment of
infected HBCAs with NS-398 attenuated the expression of MMP-1, -3 and -9 in a dose-
dependent manner. Similarly, expression of interleukin-1b, -6 and -8, which were markedly
elevated in infected HBCAs, exhibited a significant reduction in their levels in the presence of
NS-398. These results provide direct evidence that WNV-induced COX-2/PGE2 is involved in
modulating the expression of multiple neuroinflammatory mediators, thereby directly linking
COX-2 with WNV disease pathogenesis. The ability of COX-2 inhibitors to modulate
WNV-induced COX-2 and PGE2 signalling warrants further investigation in an animal model as a
potential approach for clinical management of neuroinflammation associated with WNVE.
INTRODUCTION
West Nile virus (WNV), a mosquito-borne flavivirus that
causes lethal encephalitis, has emerged as a significant
cause of viral encephalitis in the USA (Brinton, 2002). In a
small subset of cases, WNV targets the central nervous
system (CNS), clinically progressing to meningitis, enceph-
alitis or acute flaccid paralysis syndrome, leading to
mortality in 10% of hospitalized patients and complicated
neurological sequelae in some who survive (Sejvar et al.,
2003). WNV-associated encephalitis (WNVE) in the mouse
model is characterized by disruption of the blood–brain
barrier (BBB), neuroinflammation, microglial activation
and loss of neurons (van Marle et al., 2007; Wang et al.,
2004, 2008). Inflammation in the CNS is a major hallmark
of WNVE in mice and is associated with a dramatic
increase in several pro-inflammatory cytokines such as
tumour necrosis factor alpha (TNF-a) and interleukin (IL)-
1b and -6 (Garcia-Tapia et al., 2007; Wang et al., 2004) and
chemokines such as CCL2 and CXCL10, which regulate
leukocyte trafficking into the brain (Glass et al., 2006; Klein
et al., 2005; Lim et al., 2006). Although many of these
virus-induced cytokines and chemokines play a critical role
in the recruitment of virus-specific T cells and virus
clearance in the mouse brain, increased production of pro-
inflammatory cytokines also contributes to the overall
disease pathogenesis.
In the CNS, neurons are the prime target for WNV
infection; however, infection of non-neuronal CNS cells
such as astrocytes and BBB endothelial cells has been
documented (Cheeran et al., 2005; Shrestha et al., 2003;
van Marle et al., 2007; Verma et al., 2009). Activation of
glial cells along with loss of neurons is considered a key
pathogenic feature in WNV infection in humans (Kelley
et al., 2003). Although virus infection in human glial cells is
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of immune mediators such as chemokines (CXCL10, CCL2
and CCL5) and cytokines (Cheeran et al., 2005; Glass et al.,
2005). Furthermore, cytotoxic factors secreted from WNV-
infected astrocytes can induce bystander death of naı ¨ve
neurons (van Marle et al., 2007). Our previous data also
demonstrated that WNV infection of human astrocytes
results in the induction of multiple matrix metalloprotei-
nases (MMPs), which are capable of degrading the tight
junction proteins of human brain microvascular endothe-
lial cells, thereby compromising the integrity of the BBB
model (Verma et al., 2010). Thus, although astrocytes are
one of the key players in WNV-induced neuroinflamma-
tory responses, the upstream events modulating these
inflammatory responses are not well understood.
Prostaglandin E2 (PGE2), the most abundant pros-
taglandin in the brain, is considered to play an essential
role as a local regulator of pathogenic processes in several
neurodegenerative diseases (Bazan et al., 2002; Candelario-
Jalil & Fiebich, 2008; Hickey et al., 2007). Cyclooxygenase
enzymes (COX-1 and -2) catalyse the committed step in
the conversion of arachidonic acid to PGE2. COX-1 is
expressed ubiquitously and is considered to be an isoform
responsible for homeostatic prostaglandin synthesis. By
contrast, COX-2 is rapidly induced in many cell types
including astrocytes in response to inflammatory stimuli
(Bazan, 2001; Bazan et al., 2002; Tzeng et al., 2005).
However, in the CNS, COX-2 is also expressed constitu-
tively in the hippocampal neurons (Yang & Chen, 2008).
Accumulating evidence suggests that of the two COX
isoforms, COX-2, but not COX-1, plays a crucial role in
inflammation and disease pathogenesis. PGE2 activates
several downstream inflammatory pathways via autocrine
or paracrine mechanisms, resulting in the induction of
pro-inflammatory mediators (Ferri & Ferguson, 2005;
Kyrkanides et al., 2002). Multiple downstream effects of
COX-2/PGE2 include induction of chemotactic cytokines,
mediators of BBB disruption such as MMPs and plasmin/
urokinase plasminogen activator (uPA), apoptotic death
and activation of microglia (Bazan, 2001; Bazan et al., 2002;
Im et al., 2006). Both MMPs and the plasmin/uPA system
belong to the family of multi-domain zinc-containing
serine proteases, and their increase in glial cells has been
associated with BBB disruption (Conant et al., 2004).
Treatment with COX-2 inhibitors such as NS-398 in both
in vitro and in vivo model systems can attenuate secretion
of cytokines, cell-adhesion molecules, MMP-9 and uPA,
and improve overall pathology associated with several
neurodegenerative diseases (Im et al., 2006; Iwamoto et al.,
2008; Ottino & Bazan, 2001; Pompl et al., 2003; Thomas &
Kuhn, 2005). CNS infection of other neurotropic viruses
such as human immunodeficiency virus (HIV) and
Japanese encephalitis virus (JEV) also results in increased
COX-2 and PGE2 production (Flora et al., 2006; Ghoshal
et al., 2007).
In WNV infection, once the virus enters the brain and
triggers inflammation, there is very little that can be done
to prevent disease progression. Therefore, understanding
the key molecular mechanisms by which WNV modulates
inflammation is of utmost importance in the design of
effective treatments. The extent of the host innate immune
response is critical in determining the end point of WNV
infection, i.e. virus clearance versus morbidity. As the
COX/PGE2 pathway has been demonstrated to modulate
the host innate and inflammatory response in viral
infections, a better understanding of this pathway in
WNV neuropathogenesis is warranted. Therefore, the
purpose of this study was to investigate the role of COX
enzymes and their product, PGE2, in WNV infection using
primary human brain cortical astrocytes (HBCAs) and to
determine the mechanisms by which they contribute to
neuroinflammation. Our results indicated that COX-2 and
its product, PGE2, are significantly induced in WNV-
infected HBCAs and that increased COX-2/PGE2 levels
correlate with a peak in the virus titres. Using the COX-2-
specific inhibitor NS-398, we further demonstrated that the
expression of MMPs and key inflammatory cytokines are
tightly regulated by COX-2/PGE2 levels in WNV-infected
astrocytes.
RESULTS
WNV infection induces COX-2 expression in
HBCAs in a dose- and time-dependent manner
Profound inflammatory reactions including induction of
MMPs, cytokines, chemokines and cell-adhesion molecules
have been demonstrated in WNV-infected brain cells
(Arjona et al., 2007; Glass et al., 2005; Wang et al., 2008).
COX-2, an important mediator of inflammation, can
modulate inflammatory reactions by inducing cytokines
and MMPs. In the brain, astrocytes are an important
source of COX-2 and inflammatory mediators in several
neurodegenerative diseases. Our previous study demon-
strated that WNV infection of primary HBCAs peaked at
day 2 post-infection (p.i.) and remained high up to day 4
p.i., following which there was a decline in the virus titre
(Verma et al., 2010). Therefore, in this study we analysed
the mRNA and protein expression of COX enzymes in
HBCAs at the same time points. The global response of
HBCAs infected with WNV at an m.o.i. of 5 was
determined at days 1 and 3 p.i. by cDNA microarray
analysis. As observed in Table 1, WNV infection did not
alter the expression profile of the COX-1 gene in HBCAs at
either time point, whereas increased expression of the
COX-2 gene was observed at day 1 and peaked further at
day 3 p.i. An increase in the expression of COX-2 was
further validated by qRT-PCR from day 1 to day 4 p.i. in
HBCAs infected with WNV at an m.o.i. of 1 and 5. As
observed in Table 1, WNV infection at an m.o.i. of 1
induced a time-dependent increase in the mRNA expres-
sion of COX-2 from day 1 to day 4 p.i. This increase was
first detected at day 1, increased sharply at day 2 and
remained high up to day 4 p.i. In concurrence with the
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5, a gradual increase in COX-2 gene expression was
observed from day 1 to day 3 p.i. Moreover, infection with
UV-inactivated WMV did not induce COX-2 expression
(Table 1), suggesting that increased COX-2 expression is a
result of active virus replication. Expression of COX-2
protein was characterized by Western blotting. As demon-
strated in Fig. 1, although COX-2 protein expression in
control HBCAs was minimal, a dramatic increase was
observed in infected HBCAs at days 2 and 3 p.i., which
coincided with high mRNA transcripts and a peak in virus
replication.
We next analysed the increase in COX-2 protein expression
by immunocytochemical analysis. Whilst mock-infected
HBCAs did not exhibit a COX-2 fluorescence signal (Fig.
2a), a strong signal for COX-2 expression was observed at
day 2 p.i. in WNV-infected HBCAs (Fig. 2b). Fig. 2(c)
demonstrates WNV antigen staining in HBCAs, and, as
depicted in Fig. 2(d), increased COX-2 immunostaining
was observed mostly in WNV-infected cells. This was
further confirmed by counting the number of COX-2- and
WNV-positive cells. Based on the counting of approxi-
mately 1000 cells from a total of four coverslips, it was
found that 79% of COX-2-positive cells were also positive
for WNV antigen staining.
Treatment with COX-2 inhibitor prevents
WNV-induced PGE2 production in HBCAs
As PGE2 is the main product of COX-2 and is released
extracellularly, it was important to determine its release in
the supernatant by ELISA. We observed a four- to fivefold
increase in PGE2 levels in the supernatant of WNV-
infected HBCAs at day 3 p.i. (P,0.01, Fig. 3). To further
confirm the contribution of COX-2 as the main source of
PGE2, infected HBCAs were treated with 25 and 50 mM
concentrations of the COX-2-specific inhibitor NS-398,
and PGE2 levels were assayed at the same time point. As
seen in Fig. 3, the level of PGE2 released by infected
HBCAs was significantly reduced in the presence of both
doses of NS-398 (P,0.01, compared with infected HBCAs
without NS-398 treatment). The inhibition was greater
in cells treated with 50 mM NS-398, suggesting a dose-
dependent effect. HBCAs infected in the presence of
vehicle control (0.001% DMSO) did not exhibit any
change in expression levels of COX-2 enzyme (data not
shown), thus validating the specificity of NS-398 in block-
ing the COX-2 enzyme. This observation is similar to
previous studies where the vehicle control for NS-398 had
no effect on the COX-2 enzyme (Baek et al., 2007; Lu et al.,
2008). These findings suggested that the increased levels of
PGE2 observed in WNV-infected cells were indeed
dependent on COX-2 activation and were not a result of
cellular COX-1 activity, which is not inhibited by NS-398.
Furthermore, NS-398 treatment did not affect the virus
titres in infected HBCAs as measured by plaque assay (data
not shown). Taken together, these results demonstrated
that WNV infection induces COX-2 and PGE2 production
in astrocytes.
WNV-induced COX-2/PGE2 regulates the
expression of uPA and MMPs in HBCAs
We have demonstrated previously that WNV infection
induces MMP-1, -3 and -9 in HBCAs (Verma et al., 2010).
As the COX-2/PGE2 signalling pathway is associated with
the induction of MMPs, we assessed the ability of WNV-
induced COX-2 and PGE2 to modulate MMP expression
in HBCAs. The mRNA expression of MMP-1, -3 and -9
increased in HBCAs at day 3 p.i. (m.o.i. 5), thereby
Table 1. mRNA fold changes in COX-1 and -2 levels in WNV-infected HBCAs compared with uninfected controls as determined by
cDNA microarray analysis and qRT-PCR
UV-WNV, UV-inactivated WNV; ND, not done.
Days p.i. COX-1 COX-2
cDNA microarray cDNA microarray Real-time qRT-PCR
m.o.i. 1 m.o.i. 5 UV-WNV
Day 1 1.01 55 27 42 1.27
Day 2 ND ND 55 87 2.1
Day 3 0.47 102 83 93 1.1
Day 4 ND ND 76 97 1.6
Fig. 1. WNV induces COX-2 protein expression in HBCAs. Cell
lysates extracted from WNV-infected (m.o.i. 5) (I) and mock-
infected control (C) HBCAs at days 2 and 3 p.i. were separated by
PAGE, transferred onto PVDF membranes and immunoblotted
with antibodies specific to COX-2. Equal loading was confirmed
by reprobing with anti-b-actin antibody and the bands were
detected by an ECL method.
WNV-induced cyclooxygenase-2 and neuroinflammation
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infected HBCAs with NS-398 drastically reduced the
expression of MMPs in a dose-dependent manner (Fig.
4a). Compared with WNV-infected cells, treatment of
infected HBCAs with NS-398 at a concentration of 50 mM
decreased the mRNA expression of MMP-3 by 55% and of
MMP-1 and -9 by 70–75%. Furthermore, a similar
inhibitory effect of NS-398 was also observed in the
amount of MMP-3 and -9 secreted into the supernatant of
infected HBCAs as assayed by ELISA. As observed in Fig.
4(b), whilst the levels of MMP-3 and -9 increased by five-
to sixfold (P,0.005) in the supernatant of infected HBCAs
at day 3 p.i., the presence of NS-398 at concentrations of 25
and 50 mM decreased their levels significantly, thereby
supporting the qRT-PCR data. These results collectively
indicated that COX-2/PGE2 modulates the expression of
MMPs in WNV-infected HBCAs. As the activation of uPA/
uPA receptor (uPAR) system, which is associated with
matrix degradation, is also governed by COX-2, we
analysed the response of uPA gene expression to WNV
infection. As depicted in Fig. 4(a), the expression of uPA
increased by four- to fivefold in WNV-infected HBCAs
compared with control cells and treatment of infected
HBCAs with NS-398 almost completely blocked any
increase in uPA mRNA.
Expression of inflammatory cytokines is governed
by COX-2-derived PGE2
Increased production of inflammatory cytokines is another
major neuropathological event associated with WNV infec-
tion. Therefore, we next investigated the possibility of COX-2
as one of the cellular factors responsible for modulating
cytokine production in WNV-infected HBCAs. Increases in
pro-inflammatory cytokines such as IL-1b and -6 has been
documented recently in WNV-infected astrocytes (van Marle
et al., 2007). Here, we measured both mRNA and protein
levels of key inflammatory cytokines such as IL-1b,- 6a n d- 8
inducedby WNV in HBCAsin the presence or absence of NS-
398. At an m.o.i. of 5, the levels of mRNA expression of IL-1b,
-6 and -8 increased by 5211-fold at 24 h p.i. (data not
shown), followed by a dramatic increase at day 2, which
peaked further at day 3 p.i. (Table 2). This sharp increase in
IL-1b,- 6a n d- 8o c c u r r e da td a y s2a n d3p . i .w h e nt h e
expression of COX-2 was also high (Fig. 1) and coincided
with the peak in virus titres. However, as depicted in Table 2,
treatment of HBCAs with NS-398 led to a 60–90% reduction
in mRNA expression of these cytokines at both time points.
This decrease was more prominent in HBCAs treated with
50 mM NS-398 compared with treatment with 25 mMN S -
398, suggesting that the reduction in cytokine expression is
dose dependent. As cytokines are secretory proteins, their
release into the supernatant of infected HBCAs treated with
or without NS-398 was confirmed by ELISA. A significant
increase in the levels of IL-1b,- 6a n d- 8w a so b s e r v e di nt h e
supernatant from WNV-infected HBCAs at day 3 p.i.
Fig. 2. Localization of COX-2 in WNV-infected HBCAs using immunofluorescence. Confluent primary HBCAs were infected
with WNV at an m.o.i. of 5 and stained with anti-COX-2 (red) or anti-WNV envelope (green) antibody and the nuclei
counterstained with DAPI (blue). (a) Mock-infected HBCAs demonstrated faint and diffused COX-2 immunoreactivity. (b) A
marked increase in COX-2 immunostaining was observed in infected HBCAs at day 2 p.i. (c) WNV-infected HBCAs stained for
WNV antigen. (d) Strong COX-2 staining was observed mostly in WNV-infected HBCAs. (e) HBCAs incubated with secondary
antibody only did not demonstrate any immunostaining. The images depicted are representative results of three independent
experiments in duplicate. Bars, 10 mm.
Fig. 3. HBCA were infected at an m.o.i. of 5 in the presence or
absence of NS-398 and the supernatants collected at day 3 p.i.
were assayed by ELISA for PGE2 production. The presence of
NS-398 significantly reduced the levels of PGE2 released into the
supernatant. The data expressed are the mean concentration±SD
(pg ml
”1) of the amount of PGE2 secreted into the cell supernatant
from at least four independent experiments in duplicate. *, P,0.01
compared with uninfected control; **, P,0.05 compared with
infected cells.
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NS-398 (P,0.05, Fig. 5). These data suggested that COX-2
has a significant regulatory effect on the induction of
inflammatory cytokines in WNV-infected cells and that
blocking of COX-2 alone was sufficient to reduce the levels of
key inflammatory cytokines released from the infected cells.
DISCUSSION
Neuroinflammation and disruption of the BBB are the
common pathological features of WNVE (Sejvar et al.,
2003; Wang et al., 2004, 2008), but the upstream signalling
pathways modulating neuroinflammation are unclear. In
the present study, we investigated the upstream mecha-
nisms by which WNV modulates the expression of MMPs
as well as key inflammatory cytokines. Our results not only
highlight the fact that astrocytes respond to WNV infection
Fig. 4. COX-2 inhibitor attenuates the expression of MMPs and
uPA. (a) qRT-PCR was conducted on RNA extracted from HBCAs
treated with or without NS-398 at day 3 p.i. (m.o.i. 5) to determine
the fold change in MMP-1, -3 and -9 gene expression. Changes in
the levels of each gene were first normalized to the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene and the fold
change in infected cells compared with corresponding control
cells was calculated. Data represent the means±SD of at least four
independent experiments conducted in duplicate. (b) The super-
natant medium from WNV- and mock-infected HBCAs with or
without NS-398 treatment was analysed for total MMP-3 and -9
levels by ELISA at day 3 p.i. WNV-induced MMP-3 and -9 were
significantly reduced in the presence of 50 mM NS-398. Results
are expressed as means±SD (pg ml
”1) of the amount of MMP-3
and -9 secreted into the cell supernatant in duplicate from at least
three independent experiments. Mean comparisons were based on
extrapolated confidence intervals for at least four data points.
*, P,0.005 compared with uninfected control; **, P,0.05
compared with infected cells.
Table 2. mRNA fold changes in cytokine levels as determined
by qRT-PCR in WNV-infected HBCAs in the presence or
absence of the COX-2-specific inhibitor NS-398
Gene Day 2 Day 3
WNV WNV+NS-398 WNV WNV+NS-398
25 mM5 0 mM2 5 mM5 0 mM
IL-1b 81 18 9 187 68 32
IL-6 76 15 8 108 37 21
IL-8 48 8 3 137 22 11
Fig. 5. COX-2 inhibitor limits the expression of cytokines in WNV-
infected HBCAs. Supernatants collected from HBCAs infected in
the presence or absence of NS-398 at day 3 p.i. were analysed by
ELISA for levels of IL-1b, -6 and -8. The data are expressed as
mean concentration±SD (pg ml
”1) of the amount of protein
secreted into the supernatant from at least three independent
experiments in duplicate. *, P,0.005 compared with uninfected
control; **, P,0.05 compared with infected cells.
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tion of its substrate, PGE2, but also link its increase to
downstream pathogenic events such as induction of
matrix-degrading enzymes and inflammatory cytokines.
The COX-2 enzyme is specifically implicated as being
important in host responses to infection, and the ability of
PGE2 to modulate inflammation and the immune response
is well documented (Bazan, 2001; Candelario-Jalil &
Fiebich, 2008). COX-2 enzymic processes not only generate
PGE2 but also promote the production and release of
reactive oxygen intermediates such as oxygen radicals and
nitric oxide (Gebicke-Haerter, 2001) and are a major target
of widely prescribed non-steroidal anti-inflammatory
drugs and newer COX-2-specific inhibitors such as
celecoxib. We have demonstrated for the first time that
the COX-2 enzyme is induced at both the mRNA and
protein level in human astrocytes (Fig. 1). This increase
coincided with a peak in virus titres, and infection with
UV-inactivated WNV failed to induce COX-2 in HBCAs,
suggesting that induction of COX-2 is a result of active
virus replication. The increase in COX-derived PGE2 as
observed in Fig. 3 also correlated with COX-2 induction,
and its dramatic decrease in the presence of the COX-2-
specific inhibitor NS-398 clearly indicated that COX-2,
rather than COX-1, was the source of PGE2 in HBCAs. It is
likely that COX-2-derived PGE2 acts as an autocrine or
paracrine molecule, thereby mediating cellular events
involved in WNV-induced neuroinflammatory responses.
Although our in vitro data identified astrocytes as one of
the sources of COX-2 in infected brain, it is possible that in
vivo other cell types such as microglia and infiltrating
monocytes may also contribute to the increased COX-2/
PGE2 levels. A recent study by Alvarez et al. (2008)
demonstrated that COX-2 induced by HIV-2 in human
astrocytes modulated their activation status, such as
expression of glial fibrillary acidic protein, and that this
effect was blocked by NS-398 treatment. Increased COX-2/
PGE2 has been linked to pathogenesis associated with other
viruses such as HIV (Flora et al., 2006), hepatitis C virus
(Lu et al., 2008), Epstein–Barr virus (Murono et al., 2001),
Theiler’s murine encephalomyelitis virus (Molina-Holgado
et al., 2002), vesicular stomatitis virus (VSV) (Chen et al.,
2002) and respiratory syncytial virus (Radi et al., 2010).
Recent findings also report COX-2 induction and micro-
glial activation following infection with JEV, another
flavivirus (Ghoshal et al., 2007).
The integrity of the BBB in neuroinflammation is highly
dependent on endothelial cells, production of cytokines
and matrix-degrading enzymes, and recruitment of cir-
culating inflammatory cells such as monocytes. An increase
in the levels of MMPs, key matrix-degrading enzymes, has
been linked to a compromised BBB and tight junction
protein degradation in infections with neurotropic viruses
such as HIV, herpes simplex virus and WNV (Keogh et al.,
2003; Sellner et al., 2006; Wang et al., 2008). Our previous
results also demonstrated that increased MMPs produced by
WNV-infected HBCAs are capable of digesting tight
junction proteins of endothelial cells (Verma et al., 2010).
Here, wefurther demonstrated that uPAis induced by WNV
in HBCAs. Increased uPA observed in neurodegenerative
diseases and infection with pathogens (Conant et al., 2004;
East et al., 2005; Paul et al., 2005) is believed to activate
plasmin, which can degrade most components of basal
lamina either directly or through activation of pro-
collagenases such as MMP-3 (Iwamoto et al., 2008; Zhao
et al., 2008). These data suggest that several matrix-
degrading components such as MMPs and uPA are induced
in the astrocytes in response to WNV infection, which
collectively might contribute to the BBB disruption in vivo.
Upstream signalling mechanisms that govern expression of
these matrix-degrading enzymes include COX-2 and
cytokines such as IL-1b and TNF-a (Aid et al., 2010;
Johnatty et al., 1997). Inhibition of COX-2 limits lipo-
polysaccharide-induced MMP-3 and -9 levels in both in
vitro and in vivo mouse models (Aid et al., 2010; Candelario-
Jaliletal.,2007).Similarly,in infectionswith pathogenssuch
as Helicobacter pylori, the COX-2/PGE2 pathway is involved
in the induction of the uPA/uPAR signalling pathway
(Iwamoto et al., 2008). Our results demonstrating a
significant reduction in the levels of MMPs and uPA in
the presence of NS-398, as depicted in Fig. 4, suggest that
WNV-induced COX-2 and its product, PGE2, are one of the
keyupstream signals that govern theactivity of these matrix-
degrading enzymes. However, these studies do not address
the question of whether these MMPs are induced directly by
PGE2 or by PGE2-modulated cytokines such as IL-1b.
Treatment with TNF-a results in the induction of MMPs
and BBB disruption in mice, and the use of COX-2-specific
inhibitors can eliminate TNF-a-induced MMP activity and
reverseBBB disruption,therebysupportingtheroleofCOX-
2 in governing MMP activities (Candelario-Jalil et al., 2007).
Similarly, post-ischaemic treatment with the COX-2 inhib-
itor nimesulide reduces BBB disruption and leukocyte
infiltration following transient focal cerebral ischaemia in
rats (Candelario-Jalil et al., 2005).
Pro-inflammatory cytokines such as TNF-a and IL-1 have
been reported as potent inducers of neuronal injury in
several neurodegenerative diseases such as cerebral isch-
aemia, spinal cord injury, multiple sclerosis and viral
infections including HIV and JEV (Brabers & Nottet, 2006;
Ghoshal et al., 2007; McColl et al., 2008). WNV infection
also results in dramatic increases of several pro-inflam-
matory cytokines and chemokines such as IL-1b and
CXCL10 in both human brain cells and mouse brain
(Garcia-Tapia et al., 2007; Kumar et al., 2010). Our data
demonstrating an increase in IL-1b in infected astrocytes is
consistent with a previous observation reported by van
Marle et al. (2007) where they not only documented
increased production of IL-1b by WNV-infected astrocytes
but also established the role of astrocyte-derived neuro-
toxic mediators in inducing the death of naı ¨ve neurons
(van Marle et al., 2007). Expression of IL-6 and -8, which
are endogenous pyrogens exerting multiple downstream
inflammatory signalling pathways, is elevated in many CNS
S. Verma, M. Kumar and V. R. Nerurkar
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mechanisms that control the production of different
cytokines are complex and include COX-2-derived PGE2,
intracellular potassium levels and reactive oxygen species
(Aktas et al., 2007; Flora et al., 2006; Salminen et al., 2008).
Cytokines such as TNF-a and IL-1b can stimulate the
expression of several secondary cytokines and COX-2. In
contrast, it is also well established that COX-2-derived
PGE2 can amplify the signalling cascade and production of
cytokines, MMPs and cell-adhesion molecules (Kyrkanides
et al., 2002; Mark et al., 2001; Tzeng et al., 2005). Similarly,
PGE2 mediates the cellular effects of IL-1b on parvocellular
neurons in the hypothalamus, and the presence of NS-398
can abolish that effect (Ferri & Ferguson, 2005). Virus
infections can induce multiple signalling pathways, which
may cross-talk with each other or converge on common
downstream effectors. In WNV infection, the initial
stimulus for cytokine production in the brain is not clear.
In the present study, our data demonstrating the ability of
NS-398 to significantly block the production and release of
IL-1b, -6 and -8 (Fig. 5) indicate that COX-2/PGE2 is one
of the pathways through which expression of key
inflammatory cytokines is modulated in WNV-infected
HBCAs. This finding is particularly important because it
suggests that targeting COX-2 alone is likely to reduce
multiple neuroinflammatory downstream molecules that
contribute to complex pathological events such as
chemoattraction of peripheral immune cells into the
CNS, disruption of the BBB and neuronal injury.
NS-398 administration to modulate inflammation has been
employed successfully in several neurodegenerative disease
models and significantly attenuates levels of several inflam-
matory mediators (Bazan et al., 2002; Candelario-Jalil &
Fiebich, 2008), thus establishing a complex feedback
regulation. Furthermore, it is COX-2 activity, but not COX-
1 activity, that contributes to the progression of focal
ischaemic brain injury, and the beneficial effects observed
with non-selective COX inhibitors are associated with COX-2
rather than COX-1 inhibition (Candelario-Jalil et al., 2003).
Although the data are limited, a few studies have character-
ized the relative effects of COX-1 and COX-2 in modulating
the host immune response (Aid et al., 2010; Candelario-Jalil
et al., 2003). In influenza virus infection, important but
opposite effects of the COX-1 and COX-2 enzymes have been
documented, wherein COX-1 deficiency is detrimental to the
host whilst COX-2 deficiency is beneficial (Carey et al., 2005).
Similarly, selective inhibition of COX-2 also suppresses
replication of VSV (Chen et al., 2000, 2002).
It has been suggested that it is the overwhelming
inflammatory response that contributes to the severity of
WNV disease, blocking of which not only improves disease
parameters but also reduces virus titres in the brain (Wang
et al., 2004, 2008). Several of these cytokines act
synergistically, resulting in cell death; therefore, it is
important to identify upstream mechanism(s) by which
the production of inflammatory molecules is modulated in
WNV infection. Extrapolation of our results to animal
models and testing the effect of COX-2 inhibitors on WNV
titres, BBB disruption and CNS inflammation ultimately
resulting in improved WNV disease outcome are war-
ranted. In conclusion, our findings establish a critical role
for COX-2 and PGE2 in modulating the inflammatory
response in the CNS to WNV infection.
METHODS
Cells and virus. Primary HBCAs were obtained from the Applied
Cell Biology Research Institute (Kirkland, WA, USA) and propagated
as described previously (Verma et al., 2010). All experiments were
performed with cells between passage 6 and 10. Infections with WNV
(lineage I, WNV strain NY99 originally isolated from crow brain and
passaged once in Vero cells) and UV-inactivated WNV were
conducted as described previously (Verma et al., 2008, 2009) and
cells were harvested at various time points p.i.
Treatment of HBCAs with COX-2 inhibitor. The toxicity of the
COX-2-specific inhibitor NS-398 (Cayman Chemical) was tested by
cultivating HBCAs in medium in the presence of NS-398 in a
concentration range of 10–80 mM using a CellTiter 96 AQueous One
Solution Cell Proliferation Assay kit (Promega) (Verma et al., 2008).
None of these concentrations of NS-398, or use of vehicle only
(0.001% DMSO), was found to be toxic to HBCAs. For all inhibitor
experiments, HBCAs were treated with 25 or 50 mM NS-398 at 12 h
p.i. with a final concentration of DMSO of 0.001%.
qRT-PCR. cDNA prepared from total RNA extracted from HBCAs
was used for qRT-PCR as described previously (Verma et al., 2010).
The primer sequences and annealing temperatures used for the
amplification of GAPDH and MMPs have been described previously
(Verma et al., 2009), and the primers for COX and inflammatory
cytokines are described in Supplementary Table S1 (available in JGV
Online). For all in vitro fold change analyses, the housekeeping gene
GAPDH was used as an internal baseline reference to normalize each
gene of interest, and the mRNA fold change of the gene of interest was
determined at each time point compared with its corresponding
infected control. All experiments were performed on samples from at
least three independent infections in duplicate.
Western immunoblot analysis of COX-2. Total protein from
HBCAs was extracted as described previously (Verma et al., 2008,
2009, 2010). The nitrocellulose membranes were incubated with
rabbit polyclonal anti-COX-2 antibody (1 mg ml
21; Santa Cruz
Biotechnologies) followed by HRP-conjugated secondary antibody
and developed using an ECL detection kit (Pierce Technologies).
Immunocytochemical analysis. Fixed HBCAs were immunos-
tained using anti-3.67G WNV envelope mAb (diluted 1:800; a
generous gift from Dr D. Gubler, Duke-NUS Graduate Medical
School, Singapore; originally produced by Dr R. H. Hall, University of
Queensland, St Lucia, Australia) or anti-COX-2 (diluted 1:100) mAb
followed by secondary antibodies conjugated to Alexa Fluor 488 or
546 (Invitrogen) and examined using a Zeiss confocal Pascal
microscope equipped with a Zeiss Axiovert 200, as described
previously (Verma et al., 2009).
Analysis of PGE2, MMPs and cytokines by ELISA. At day 4 p.i.,
the supernatant medium from WNV- and mock-infected HBCAs in
the presence or absence of NS-398 was collected to assay the levels of
PGE2, MMPs and cytokines. All ELISAs were performed using
undiluted supernatant medium in Biosafety Level 3 laboratories
without any UV treatment. PGE2 was measured using a PGE2
Parameter kit (R&D Systems) according to the manufacturer’s
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http://vir.sgmjournals.org 513instructions. ELISAs for total MMP-3 and -9 in the cell supernatant
were conducted using Quantikine human MMP-3 and -9 ELISA kits,
respectively (R&D systems), as described previously (Verma et al.,
2010). IL-6 and -8 levels were measured using Quantikine ELISA kits,
whilst the IL-1b level was measured using a Quantikine High
Sensitivity kit according to the manufacturer’s instructions. The
ELISA plates were analysed using a Victor 3 microtitre reader
equipped with Workout version 1.5 software (Perkin Elmer).
Statistical analysis. All in vitro data are reported as the mean±SD of
at least three independent experiments in duplicate. An unpaired
Student t-test using GraphPad Prism software version 5.0 was used to
compare the levels of cytokines and MMPs assayed by ELISA.
Differences where P,0.05 were considered statistically significant.
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